

# GEORGIAN MEDICAL NEWS

---

ISSN 1512-0112

NO 7-8 (364-365) Июль-Август 2025

---

ТБИЛИСИ - NEW YORK



ЕЖЕМЕСЯЧНЫЙ НАУЧНЫЙ ЖУРНАЛ

Медицинские новости Грузии  
საქართველოს სამედიცინო სიახლენი

## GEORGIAN MEDICAL NEWS

Monthly Georgia-US joint scientific journal published both in electronic and paper formats of the Agency of Medical Information of the Georgian Association of Business Press.  
Published since 1994. Distributed in NIS, EU and USA.

**GMN: Georgian Medical News** is peer-reviewed, published monthly journal committed to promoting the science and art of medicine and the betterment of public health, published by the GMN Editorial Board since 1994. GMN carries original scientific articles on medicine, biology and pharmacy, which are of experimental, theoretical and practical character; publishes original research, reviews, commentaries, editorials, essays, medical news, and correspondence in English and Russian.

GMN is indexed in MEDLINE, SCOPUS, PubMed and VINITI Russian Academy of Sciences. The full text content is available through EBSCO databases.

**GMN: Медицинские новости Грузии** - ежемесячный рецензируемый научный журнал, издаётся Редакционной коллегией с 1994 года на русском и английском языках в целях поддержки медицинской науки и улучшения здравоохранения. В журнале публикуются оригинальные научные статьи в области медицины, биологии и фармации, статьи обзорного характера, научные сообщения, новости медицины и здравоохранения. Журнал индексируется в MEDLINE, отражён в базе данных SCOPUS, PubMed и ВИНТИ РАН. Полнотекстовые статьи журнала доступны через БД EBSCO.

**GMN: Georgian Medical News** – საქართველოს სამედიცინო სიახლენი – არის ყოველთვიური სამეცნიერო სამედიცინო რეცენზირებადი ჟურნალი, გამოიცემა 1994 წლიდან, წარმოადგენს სარედაქციო კოლეგიისა და აშშ-ის მეცნიერების, განათლების, ინდუსტრიის, ხელოვნებისა და ბუნებისმეტყველების საერთაშორისო აკადემიის ერთობლივ გამოცემას. GMN-ში რუსულ და ინგლისურ ენებზე ქვეყნდება ექსპერიმენტული, თეორიული და პრაქტიკული ხასიათის ორიგინალური სამეცნიერო სტატიები მედიცინის, ბიოლოგიისა და ფარმაციის სფეროში, მიმოხილვითი ხასიათის სტატიები.

ჟურნალი ინდექსირებულია MEDLINE-ის საერთაშორისო სისტემაში, ასახულია SCOPUS-ის, PubMed-ის და ВИНТИ РАН-ის მონაცემთა ბაზებში. სტატიების სრული ტექსტი ხელმისაწვდომია EBSCO-ს მონაცემთა ბაზებშიდან.

## WEBSITE

[www.geomednews.com](http://www.geomednews.com)

## К СВЕДЕНИЮ АВТОРОВ!

При направлении статьи в редакцию необходимо соблюдать следующие правила:

1. Статья должна быть представлена в двух экземплярах, на русском или английском языках, напечатанная через **полтора интервала на одной стороне стандартного листа с шириной левого поля в три сантиметра**. Используемый компьютерный шрифт для текста на русском и английском языках - **Times New Roman (Кириллица)**, для текста на грузинском языке следует использовать **AcadNusx**. Размер шрифта - **12**. К рукописи, напечатанной на компьютере, должен быть приложен CD со статьей.

2. Размер статьи должен быть не менее десяти и не более двадцати страниц машинописи, включая указатель литературы и резюме на английском, русском и грузинском языках.

3. В статье должны быть освещены актуальность данного материала, методы и результаты исследования и их обсуждение.

При представлении в печать научных экспериментальных работ авторы должны указывать вид и количество экспериментальных животных, применявшиеся методы обезболивания и усыпления (в ходе острых опытов).

4. К статье должны быть приложены краткое (на полстраницы) резюме на английском, русском и грузинском языках (включающее следующие разделы: цель исследования, материал и методы, результаты и заключение) и список ключевых слов (key words).

5. Таблицы необходимо представлять в печатной форме. Фотокопии не принимаются. **Все цифровые, итоговые и процентные данные в таблицах должны соответствовать таковым в тексте статьи.** Таблицы и графики должны быть озаглавлены.

6. Фотографии должны быть контрастными, фотокопии с рентгенограмм - в позитивном изображении. Рисунки, чертежи и диаграммы следует озаглавить, пронумеровать и вставить в соответствующее место текста **в tiff формате**.

В подписях к микрофотографиям следует указывать степень увеличения через окуляр или объектив и метод окраски или импрегнации срезов.

7. Фамилии отечественных авторов приводятся в оригинальной транскрипции.

8. При оформлении и направлении статей в журнал МНГ просим авторов соблюдать правила, изложенные в «Единых требованиях к рукописям, представляемым в биомедицинские журналы», принятых Международным комитетом редакторов медицинских журналов - <http://www.spinesurgery.ru/files/publish.pdf> и [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html). В конце каждой оригинальной статьи приводится библиографический список. В список литературы включаются все материалы, на которые имеются ссылки в тексте. Список составляется в алфавитном порядке и нумеруется. Литературный источник приводится на языке оригинала. В списке литературы сначала приводятся работы, написанные знаками грузинского алфавита, затем кириллицей и латиницей. Ссылки на цитируемые работы в тексте статьи даются в квадратных скобках в виде номера, соответствующего номеру данной работы в списке литературы. Большинство цитированных источников должны быть за последние 5-7 лет.

9. Для получения права на публикацию статья должна иметь от руководителя работы или учреждения визу и сопроводительное отношение, написанные или напечатанные на бланке и заверенные подписью и печатью.

10. В конце статьи должны быть подписи всех авторов, полностью приведены их фамилии, имена и отчества, указаны служебный и домашний номера телефонов и адреса или иные координаты. Количество авторов (соавторов) не должно превышать пяти человек.

11. Редакция оставляет за собой право сокращать и исправлять статьи. Корректур авторам не высылаются, вся работа и сверка проводится по авторскому оригиналу.

12. Недопустимо направление в редакцию работ, представленных к печати в иных издательствах или опубликованных в других изданиях.

**При нарушении указанных правил статьи не рассматриваются.**

## REQUIREMENTS

Please note, materials submitted to the Editorial Office Staff are supposed to meet the following requirements:

1. Articles must be provided with a double copy, in English or Russian languages and typed or computer-printed on a single side of standard typing paper, with the left margin of 3 centimeters width, and 1.5 spacing between the lines, typeface - **Times New Roman (Cyrillic)**, print size - 12 (referring to Georgian and Russian materials). With computer-printed texts please enclose a CD carrying the same file titled with Latin symbols.

2. Size of the article, including index and resume in English, Russian and Georgian languages must be at least 10 pages and not exceed the limit of 20 pages of typed or computer-printed text.

3. Submitted material must include a coverage of a topical subject, research methods, results, and review.

Authors of the scientific-research works must indicate the number of experimental biological species drawn in, list the employed methods of anesthetization and soporific means used during acute tests.

4. Articles must have a short (half page) abstract in English, Russian and Georgian (including the following sections: aim of study, material and methods, results and conclusions) and a list of key words.

5. Tables must be presented in an original typed or computer-printed form, instead of a photocopied version. **Numbers, totals, percentile data on the tables must coincide with those in the texts of the articles.** Tables and graphs must be headed.

6. Photographs are required to be contrasted and must be submitted with doubles. Please number each photograph with a pencil on its back, indicate author's name, title of the article (short version), and mark out its top and bottom parts. Drawings must be accurate, drafts and diagrams drawn in Indian ink (or black ink). Photocopies of the X-ray photographs must be presented in a positive image in **tiff format**.

Accurately numbered subtitles for each illustration must be listed on a separate sheet of paper. In the subtitles for the microphotographs please indicate the ocular and objective lens magnification power, method of coloring or impregnation of the microscopic sections (preparations).

7. Please indicate last names, first and middle initials of the native authors, present names and initials of the foreign authors in the transcription of the original language, enclose in parenthesis corresponding number under which the author is listed in the reference materials.

8. Please follow guidance offered to authors by The International Committee of Medical Journal Editors guidance in its Uniform Requirements for Manuscripts Submitted to Biomedical Journals publication available online at: [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)  
[http://www.icmje.org/urm\\_full.pdf](http://www.icmje.org/urm_full.pdf)

In GMN style for each work cited in the text, a bibliographic reference is given, and this is located at the end of the article under the title "References". All references cited in the text must be listed. The list of references should be arranged alphabetically and then numbered. References are numbered in the text [numbers in square brackets] and in the reference list and numbers are repeated throughout the text as needed. The bibliographic description is given in the language of publication (citations in Georgian script are followed by Cyrillic and Latin).

9. To obtain the rights of publication articles must be accompanied by a visa from the project instructor or the establishment, where the work has been performed, and a reference letter, both written or typed on a special signed form, certified by a stamp or a seal.

10. Articles must be signed by all of the authors at the end, and they must be provided with a list of full names, office and home phone numbers and addresses or other non-office locations where the authors could be reached. The number of the authors (co-authors) must not exceed the limit of 5 people.

11. Editorial Staff reserves the rights to cut down in size and correct the articles. Proof-sheets are not sent out to the authors. The entire editorial and collation work is performed according to the author's original text.

12. Sending in the works that have already been assigned to the press by other Editorial Staffs or have been printed by other publishers is not permissible.

**Articles that Fail to Meet the Aforementioned  
Requirements are not Assigned to be Reviewed.**

## ავტორთა საყურადღებო!

რედაქციაში სტატიის წარმოდგენისას საჭიროა დავიცვათ შემდეგი წესები:

1. სტატია უნდა წარმოადგინოთ 2 ცალად, რუსულ ან ინგლისურ ენებზე, დაბეჭდილი სტანდარტული ფურცლის 1 გვერდზე, 3 სმ სიგანის მარცხენა ველისა და სტრიქონებს შორის 1,5 ინტერვალის დაცვით. გამოყენებული კომპიუტერული შრიფტი რუსულ და ინგლისურენოვან ტექსტებში - **Times New Roman (Кириллица)**, ხოლო ქართულენოვან ტექსტში საჭიროა გამოვიყენოთ **AcadNusx**. შრიფტის ზომა – 12. სტატიას თან უნდა ახლდეს CD სტატიით.

2. სტატიის მოცულობა არ უნდა შეადგენდეს 10 გვერდზე ნაკლებს და 20 გვერდზე მეტს ლიტერატურის სიის და რეზიუმეების (ინგლისურ, რუსულ და ქართულ ენებზე) ჩათვლით.

3. სტატიაში საჭიროა გაშუქდეს: საკითხის აქტუალობა; კვლევის მიზანი; საკვლევი მასალა და გამოყენებული მეთოდები; მიღებული შედეგები და მათი განსჯა. ექსპერიმენტული ხასიათის სტატიების წარმოდგენისას ავტორებმა უნდა მიუთითონ საექსპერიმენტო ცხოველების სახეობა და რაოდენობა; გაუტკივარებისა და დაძინების მეთოდები (მწვავე ცდების პირობებში).

4. სტატიას თან უნდა ახლდეს რეზიუმე ინგლისურ, რუსულ და ქართულ ენებზე არანაკლებ ნახევარი გვერდის მოცულობისა (სათაურის, ავტორების, დაწესებულების მითითებით და უნდა შეიცავდეს შემდეგ განყოფილებებს: მიზანი, მასალა და მეთოდები, შედეგები და დასკვნები; ტექსტუალური ნაწილი არ უნდა იყოს 15 სტრიქონზე ნაკლები) და საკვანძო სიტყვების ჩამონათვალი (key words).

5. ცხრილები საჭიროა წარმოადგინოთ ნაბეჭდი სახით. ყველა ციფრული, შემავსებელი და პროცენტული მონაცემები უნდა შეესაბამებოდეს ტექსტში მოყვანილს.

6. ფოტოსურათები უნდა იყოს კონტრასტული; სურათები, ნახაზები, დიაგრამები - დასათაურებული, დანომრილი და სათანადო ადგილას ჩასმული. რენტგენოგრაფიის ფოტოსურათები წარმოადგინეთ პოზიტიური გამოსახულებით **tiff** ფორმატში. მიკროფოტოსურათების წარწერებში საჭიროა მიუთითოთ ოკულარის ან ობიექტივის საშუალებით გადიდების ხარისხი, ანათალების შედეგების ან იმპრეგნაციის მეთოდი და აღნიშნოთ სურათის ზედა და ქვედა ნაწილები.

7. სამამულო ავტორების გვარები სტატიაში აღინიშნება ინიციალების თანდართვით, უცხოურისა – უცხოური ტრანსკრიპციით.

8. სტატიას თან უნდა ახლდეს ავტორის მიერ გამოყენებული სამამულო და უცხოური შრომების ბიბლიოგრაფიული სია (ბოლო 5-8 წლის სიღრმით). ანბანური წყობით წარმოდგენილ ბიბლიოგრაფიულ სიაში მიუთითეთ ჯერ სამამულო, შემდეგ უცხოელი ავტორები (გვარი, ინიციალები, სტატიის სათაური, ჟურნალის დასახელება, გამოცემის ადგილი, წელი, ჟურნალის №, პირველი და ბოლო გვერდები). მონოგრაფიის შემთხვევაში მიუთითეთ გამოცემის წელი, ადგილი და გვერდების საერთო რაოდენობა. ტექსტში კვადრატულ ფხიხლებში უნდა მიუთითოთ ავტორის შესაბამისი N ლიტერატურის სიის მიხედვით. მიზანშეწონილია, რომ ციტირებული წყაროების უმეტესი ნაწილი იყოს 5-6 წლის სიღრმის.

9. სტატიას თან უნდა ახლდეს: ა) დაწესებულების ან სამეცნიერო ხელმძღვანელის წარდგინება, დამოწმებული ხელმოწერითა და ბეჭდით; ბ) დარგის სპეციალისტის დამოწმებული რეცენზია, რომელშიც მითითებული იქნება საკითხის აქტუალობა, მასალის საკმაობა, მეთოდის სანდოობა, შედეგების სამეცნიერო-პრაქტიკული მნიშვნელობა.

10. სტატიის ბოლოს საჭიროა ყველა ავტორის ხელმოწერა, რომელთა რაოდენობა არ უნდა აღემატებოდეს 5-ს.

11. რედაქცია იტოვებს უფლებას შეასწოროს სტატია. ტექსტზე მუშაობა და შეჯერება ხდება საავტორო ორიგინალის მიხედვით.

12. დაუშვებელია რედაქციაში ისეთი სტატიის წარდგენა, რომელიც დასაბეჭდად წარდგენილი იყო სხვა რედაქციაში ან გამოქვეყნებული იყო სხვა გამოცემებში.

აღნიშნული წესების დარღვევის შემთხვევაში სტატიები არ განიხილება.

Babry I. Oren, Marina I. Devdariani, Gela V. Beselia, Nino N. Sikharulidze, Manana G. Dashniani, Maia A. Burjanadze, Ia R. Kvachakidze, Marina I. Nebieridze, Lena Sh. Davlianidze, Lali M. Gumberidze, Nodar P. Mitagvaria. ROLE OF ANTIOXIDANT FOLIUM EXPOSURE ON OXIDATIVE STRESS IN A VALPROIC ACID-INDUCED ANIMAL MODEL OF AUTISM.....	6-15
Hajdi Gorica, Pavlo Djamandi, Gentian Vyshka. DELAYED ONSET OF MYASTHENIA GRAVIS FOLLOWING COLECTOMY FOR ULCERATIVE COLITIS: A CASE STUDY.....	16-17
Zhadyra Yersariyeva, Bagdad Suleyeva, Botagoz Turdaliyeva, Yeldos Tussipbayev. HEMOSTASIS GENE POLYMORPHISM IN RETINAL VASCULAR OCCLUSION: A SYSTEMATIC REVIEW.....	18-28
Ilia Nakashidze, Nameera Parveen Shaikh, Shota Nakashidze, Aleena Parveen Shaikh, Sarfraz Ahmad, Irina Nakashidze. EVALUATION OF TNF- $\alpha$ LEVELS IN MALE PATIENTS WITH STROKE: PROGNOSTIC IMPLICATIONS.....	29-32
Yerbolat Iztleuov, Marat Iztleuov, Altynbek Dushmanov, Gulmira Iztleuova. PREVENTION IN THE PARENTAL GENERATION OF EXPOSED RATS: CONSEQUENCES OF TOXIC EXPOSURE TO CHROMIUM AND GAMMA IRRADIATION IN AN EXPERIMENTAL MODEL.....	33-45
Rashid Nassar, Nadine Khayyat, Michele Halasa, Fahad Hussain. TRAUMATIC ANTERIOR SHOULDER INSTABILITY (TUBS): A NARRATIVE REVIEW OF CURRENT LITERATURE.....	46-50
Albadawi Abdelbagi Talha, Mawaheip A. Abdo Jeweser, Abubakr Ali Elamin Mohamed Ahmed, Abdelrahman Eldaw Mohammed, Elhadi Abdalla Ahmed, GadAllah Modawe, Sanaa Elfatih Hussein. THE HBV AND HCV SEROPREVALENCE AMONG BLOOD DONORS IN AI-DAMAZIN STATE, SUDAN: A THREE-YEAR RETROSPECTIVE STUDY.....	51-54
Hiba Salah Hasan, Teeb Ali, Kadhim Adnan Ali, Al Hassan Ali, Hany A. Al-hussaniy. MODELING DRUG-ORGAN INTERACTIONS AND OPTIMIZING IMMUNOTHERAPY: A QUANTITATIVE SYSTEMS PHARMACOLOGY AND ODRONEXTAMAB DYNAMICS.....	55-60
Zilola Mavlyanova, Davron Ravshanov, Malika Ibragimova, Lola Irbutaeva, Khalimova Fariza, May K. Ismail, Shawgi A. Elsiddig, Marwan Ismail, Salma E R Mohamed, Sara Mohammed Ali. PROGNOSTIC SIGNIFICANCE OF PROLIFERATION (KI-67) AND ANGIOGENESIS (CD34) MARKERS IN MENINGIOMAS FOR THE DEVELOPMENT OF REHABILITATION STRATEGIES.....	61-65
A.R. Abzaliyeva, K.K. Kurakbayev, A.R. Ryskulova, Z.R. Abzaliyev, E. Tasmagambet, D.Zh. Saussanova. TURNOVER INTENTIONS AMONG PHYSICIANS AND NURSES IN KAZAKHSTAN DURING THE COVID-19 PANDEMIC: A CROSS-SECTIONAL STUDY OF PSYCHOLOGICAL AND PROFESSIONAL CHALLENGES.....	66-72
A.A. Mammadov, A.N. Mustafayev, A.H. Aliyev. RADIOLOGICAL IMAGING METHODS FOR ACCURATE DIAGNOSIS OF ABDOMINAL POSTOPERATIVE COMPLICATIONS.....	73-76
I.A. Lebedev, E.V. Zakharchuk, Yu.V. Boldyreva, I.A. Aptekar, E.I. Malinina. OSSIFICATION OF THE POSTERIOR LONGITUDINAL LIGAMENT: A CASE REPORT AND LITERATURE REVIEW.....	77-79
Zhanar Balmukhamedova, Gulmira Derbissalina, Aliya Dzholdasbekova, Dariga Blyalova, Luiza Murzakhalova. SPECKLE-TRACKING ECHOCARDIOGRAPHY FOR EARLY DETECTION OF SUBCLINICAL SYSTOLIC DYSFUNCTION IN PERIMENOPAUSAL WOMEN WITHOUT APPARENT DIASTOLIC DYSFUNCTION.....	80-86
Arkam Thabit Al Neama, Musab Mohammed Khalaf, Ahmed A.J. Mahmood. PATTERNS OF ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE ACTIVITY IN COMMON CARDIOVASCULAR PHENOTYPES.....	87-94
Argjira Veseli, Shefqet Mrasori, Ivana Čuković-Bagić, Lul Raka, Kaltrina Veseli, Enis Veseli. PARENTAL QUALITY OF LIFE WHEN RAISING CHILDREN WITH AUTISM SPECTRUM DISORDER: A NARRATIVE REVIEW.....	95-100
Anas Ali Alhur, Daliya T. Sendi, Miad M. AlZahrani, Layla T. Abusharha, Rahaf Y. Abudaak, Rahmah Alsinan, Rama R. Alharbi, Lamia Almadhi, Laila M. Alotaibi, Mona A. Hadadi, Shaima H. Alattas, Fatimah Almisbah, Fathi Almisbah, Abdulrahman Alrashed, Kawkab Alharbi. EVALUATING THE TRUSTWORTHINESS OF CHATGPT-GENERATED HEALTH INFORMATION AMONG FUTURE HEALTH CARE PROFESSIONALS.....	101-106
Ting-Ting Wang, Yan Wang. HUMANISTIC CARE NURSING FOR PATIENTS IN THE OPERATING ROOM DURING THE PERIOPERATIVE PERIOD: FULL-CYCLE CARE FROM PHYSIOLOGY TO PSYCHOLOGY.....	107-109
Zauresh Barmanasheva, Mariya Laktionova, Anna Onglas, Ayaulym Kossetova, Ivan Melnikov. PREVALENCE AND RISK FACTORS OF UTERINE FIBROIDS IN WOMEN OF REPRODUCTIVE AGE: A FACILITY-BASED STUDY IN AMEGACITY.....	110-120
Bolat Ashirov, Assel Kassymova, Jamilya Mansurova, Andrey Orekhov, Meiramgul Tokbulatova, Mirgul Kapakova, Zhanar Toktarova, Aisulu Zhunuspekova. PROGNOSTIC MARKERS OF ISCHEMIC AND HEMORRHAGIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER PERCUTANEOUS CORONARY INTERVENTION.....	121-128

Khalilov Sh. Dzh. ELECTROCARDIOGRAPHY CHARACTERISTICS OF THE PATIENTS WITH NON-ST-ELEVATION MYOCARDIAL INFARCTION (NS TEMI).....	129-132
Salome Kordzaia, Elene Dolmazashvili, Khatuna Tsiklauri, Lasha Khmaladze, Nana Chikhladze. FROM INFUSION REACTION TO IMMUNE CASCADE: A CASE OF SEQUENTIAL TAXANE AND CAPECITABINE TOXICITIES IN TRIPLE-NEGATIVE BREAST CANCER.....	133-136
Yu Zhu, Fandong Zeng, Weiwei Chang, Liying Wen, Lijun Zhu, Yuelong Jin. AN EMPIRICAL STUDY ON THE ASSOCIATION BETWEEN ASPIRATION INDEX AND ACADEMIC PERFORMANCE AMONG PREVENTIVE MEDICINE STUDENTS.....	137-142
Alaa O Ahmed, Mubarak S Karsany, Mohamed Elfatih Abdelwadoud, Mutaz Ali, Osama Mohamed, Amged Gaffer Mostafa, Hussam Ali Osman, Elryah I Ali, Elyasa Elfaki, Tagwa Yousif Elsayed Yousif, Ayman H. Alfeel, Mohammed Ibrahim Saeed. MOLECULAR DETECTION OF HIGH RISK HUMAN PAPILLOMA VIRUS SUBTYPES IN CERVICAL SMEARS AMONG SUDANESE WOMEN.....	143-149
Tchernev G, Tchernev KG Jr, Krastev DS, Krastev NS, Kordeva S. DERMATOLOGIC SURGERY ROUNDS: RECONSTRUCTIVE SURGERY EMPLOYING THE SHARK ISLAND FLAP FOR BASAL CELL CARCINOMA AFFECTING THE NASAL ALA.....	150-153
Saltanat Imanalieva, Bayan Sagindykova, Rabiga Anarbayeva, Murat Omirali, Gulnara Ospanova, Murat Ashirov. CURRENT STATUS AND PROSPECTS FOR THE DEVELOPMENT OF PEDIATRIC DOSAGE FORMS BY THE EXAMPLE OF COMBINED MELOXICAM AND VITAMIN B12 TABLETS.....	154-167
Ahmed Miri Saadoun. INCIDENCE OF PRESSURE SORE IN THE INTENSIVE CARE UNIT AT AL-DIWANYIA TEACHING HOSPITAL.....	168-171
Isoyan A.S, Danielyan M.H, Antonyan I.V, Azizyan N.H, Mkrtchyan A.A, Karapetyan K.V, Nebogova K.A. MORPHOHISTOCHEMICAL ANALYSIS OF CORTICAL STRUCTURES IN AN EXPERIMENTAL MODEL OF PROLONGED COMPRESSION SYNDROME OF THE HIND LIMB IN RATS.....	172-179
Abdulaziz Alroshodi, Faisal A. Al-Harbi, Rasil Sulaiman Alayed, Fahad M. Alharbi, Khalid A Alkhalifah, Mayadah Assaf Alawajji, Ibrahim S. Alsabhawi. FACTORS IMPACTING HEMODIALYSIS TREATMENT ADHERENCE IN END-STAGE RENAL DISEASE PATIENTS RECEIVING IN- CENTER HEMODIALYSIS IN QASSIM REGION.....	180-187
Gulshat Alimkhanova, Marat Syzdykbayev, Rinat Ashzhanov, Kulsara Rustemova, Maksut Kazymov, Rustem Kazangapov, Asem Kazangapova, Saule Imangazinova, Yernar Kairkhanov, Bazar Tuleuov, Sanzhar Khalelov, Roman Khripunov, Samatbek Abdrakhmanov, Abay Mijatov. THE TRANSVERSUS ABDOMINIS PLANE BLOCK AS A METHOD OF MULTIMODAL OPIOID-SPARING POSTOPERATIVE ANALGESIA: A NARRATIVE REVIEW.....	188-194
Zhengmei Fang, Xiaoling Ran, Lijun Zhu, Yingshui Yao, Yuelong Jin. THE IMPACT OF BMAL1 GENE POLYMORPHISM ON SLEEP QUALITY IN HEALTHY CHINESE YOUTH: A GENDER-SPECIFIC ANALYSIS.....	195-201
Muwafaq H. Zaya, Ahmed A. J. Mahmood, Musab M. Khalaf. CROSS SECTIONAL EVIDENCE FOR OPPOSING EFFECTS OF HYPERGLYCAEMIA AND HYPERLIPIDAEMIA ON CHOLINESTERASE ACTIVITIES.....	202-210
Erleta Muçaj, Erëza Durmishi, Serbeze Kabashi Muçaj, Leart Kuçi, Elza Muçaj, Gerta Durmishi. CHALLENGES IN RADIOLOGICAL DIAGNOSIS: CRANIOPHARYNGIOMA VS ASTROCYTOMA.....	211-214
Uday Mahajan, Imran Khan, Ria Gupta, Meraj Akhtar, Vibhore Gupta, Edward Spurrier, Mohamed Kabary, Adnan Asif, Salman Shoukat Ali Parpia. NAMING CONVENTIONS FOR UNIDENTIFIED PATIENTS IN EMERGENCY AND TRAUMA SETTINGS: A NARRATIVE REVIEW.....	215-218
Xuexue Li, Wenjie Wen, Dandan Ren. MOLECULAR MECHANISMS OF DIABETIC PERIODONTITIS: IDENTIFICATION OF KEY OXIDATIVE STRESS-RELATED GENES AND POTENTIAL THERAPEUTIC ROLE OF METFORMIN THROUGH MMP14 AND PXDN.....	219-231
Davron Ravshanov, Zilola Mavlyanova, Kholmirezayev Bakhtiyor, Malika Tursunovna, Khalimova Fariza. HISTOPATHOLOGICAL PREDICTORS AND FUNCTIONAL RECOVERY IN PATIENTS WITH INTRACRANIAL MENINGIOMAS.....	232-240
Aymuhambetov Y, Khismetova Z A, Iskakova N, Akhmetova K, Serikova-Esengeldina D, Shalgumbayeva G.M. ASSESSMENT OF QUALITY OF LIFE IN BREAST CANCER PATIENTS BY USING EORTC QLQ-C30 QUESTIONNAIRE IN EAST KAZAKHSTAN REGION.....	241-248
Yujing Tao, Long Hua, Liu Zhang, Ying Feng, Liying Wen, Weiwei Chang. THE CORRELATION BETWEEN STRESS, ACADEMIC PERFORMANCE, AND SLEEP DISTURBANCES AMONG HIGH SCHOOL STUDENTS IN ANHUI PROVINCE: A CROSS-SECTIONAL STUDY.....	249-257
Fahad AlAmr, Muhannad Essa S. Alghamdi, Ahmed Saeed A. Alghamdi, Osama Khamis A. Alghamdi, Hassan Mahfouz B. Alghamdi, Osama Mesfer S. Alghamdi, Abdullah Ali A. Almimoni, Abdulmalik Ahmed S. Al-Zahrani. PREVALENCE AND ASSOCIATED RISK FACTORS OF NOCTURNAL ENURESIS AMONG CHILDREN AGED 5-18 YEARS IN ALBAHA REGION, SAUDI ARABIA.....	258-263

Aya Saad Aldewachi, Mohammed I Aladul. APPETITIVE TRAITS AND QUALITY OF LIFE IN WOMEN WITH OBESITY USING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: INSIGHTS FROM A PCOS-ENRICHED SAMPLE.....	264-269
George Shaburishvili, Nikoloz Shaburishvili, Georg Becker, Solomon Zeikidze, Bacho Tsiklauri. INCIDENCE OF ADVERSE EVENTS RESULTING FROM BETA-BLOCKER TITRATION IN PATIENTS WITH HEART FAILURE.....	270-279
Blushinova A.N, Orazalina A.S, Shalgumbayeva G.M. INDUCED ABORTION IN KAZAKHSTAN: WOMEN'S PERCEPTIONS AND EXPERIENCES BASED ON CROSS-SECTIONAL STUDY.....	280-288
Qunru Hu, Liying Wen, Jingqi Zhang, Weiwei Chang, Yuelong Jin, Anshi Wang, Lijun Zhu. IS CORE SELF-EVALUATION A PROTECTIVE FACTOR FOR COLLEGE STUDENTS' MARITAL ATTITUDES? THE MODERATING ROLE OF PSYCHOLOGICAL STATUS.....	289-294
Gulfariza Gani, Ubaidilla Datkhayev, Kairat Zhakipbekov, Serzhan Mombekov, Murat Ashirov, Nurgali Rakhymbayev, Zhanerke Seitova. STUDY OF THE CHEMICAL COMPOSITION AND ANTIMICROBIAL ACTIVITY OF SUBCRITICAL CO <sub>2</sub> EXTRACT FROM <i>EUPHORBIA HUMIFUSA</i> WILLD.....	295-302
Maysoon Mohammed Hassan, Mohammed Abdulwahab Ati Al-askeri, Naseer Kadhim Jawad. PROGNOSTIC IMPACT OF EGFR2 AND KI-67 OVEREXPRESSION WITH DOWNREGULATION OF <i>miR-17</i> AND <i>miR-1307</i> IN FEMALE BREAST CANCER PATIENTS.....	303-313
Imzharov Talgat Abatovich, Zhakiev Bazylbek Sagidolievich, Sarkulov Marat Nukinovich, Pavlov Valentin Nikolaevich, Kurmangaliev Oleg Maratovich. THE EFFECTIVENESS OF METAPHYLAXIS OF NEPHROLITHIASIS DURING PERCUTANEOUS NEPHROLITHOTRIPSY: A SYSTEMATIC REVIEW AND META-ANALYSIS.....	314-322
Yan Wang, Ting-Ting Wang, Chang-Sheng He. PROGRESS IN T-CELL IMMUNE RESEARCH ON HYPERLIPIDEMIC PANCREATITIS.....	323-326
Marwan I Abdullah. MINING THE CELLMINER DATABASE TO IDENTIFY SHARED BIOMARKERS OF 5-FU AND OXALIPLATIN RESPONSE.....	327-341
Shyngys Adilgazyuly, Tolky Bulegenov, Akmaral Mussakhanova, Tasbolat Adylkhanov, Kanat Abdilov, Zhannur Altybayeva, Gulmira Bazarova, Malike Kudaibergenova, Makpal Alchimbayeva, Aigul Utegenova, Gulnara Otepova. ASSESSING THE INFLUENCE OF MEDICAL EDUCATION REFORMS ON ONCOLOGIST WORKFORCE AND LUNG CANCER MORTALITY IN KAZAKH-STAN: AN INTERRUPTED TIME SERIES ANALYSIS WITH PREDICTIVE MODELING OF NATIONWIDE DATA FROM 1998 TO 2023.....	342-351
Wen-Wen Liu, Zhi-Juan Xu, Fang Xu. NEW INSIGHTS INTO THE PATHOGENESIS AND TREATMENT ADVANCES OF AGE - RELATED MACULAR DEGENERATION.....	352-354
Zhamilya Zholdybay, Zhanar Zhakenova, Madina Gabdullina, Yevgeniya Filippenko, Suria Yessentayeva, Galymzhan Alisherov, Aigerim Mustapaeva, Jandos Amankulov, Ildar Fakhradiyev. <sup>68</sup> GA-FAPI PET/CT IN DIAGNOSIS OF THE BREAST CANCER DEPENDING ON THE MOLECULAR SUBTYPES AND EXPRESSION STATUS OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2/NEU).....	355-363
A.I. Rybin, V.E. Maksymovskiy, O.V. Kuznetsova, V.V. Osyk, A.S. Bohdan. THE RESULTS OF LIFE QUALITY ASSESSMENT IN PATIENTS WITH PRIMARY OVARIAN CANCER DURING TREATMENT: EFFECT OF DIFFERENT TACTICS AND HIPEC.....	364-368
Miranda Sejdiu Abazi, Arbër Prokshaj, Shpëtim Prokshaj, Fitim Alidema, Nora Leci, Linda Abazi Morina. ASSESSMENT OF PRACTICAL PERFORMANCE IN ORTHODONTIC CLASP FABRICATION AMONG DENTAL TECHNICIAN STUDENTS AT UBT: A REAL-TIME ANALYSIS OF WORKING TIME AND PERCEIVED STRESS.....	369-377
Abylay Baimakhanov, Ainash Oshibayeva, Temirkhan Kozhakhmetov, Nazarbek Omarov, Dinara Akhmetzhanova, Berikuly Duman. RESULTS OF MEDICAL CARE FOR PERSONS WITH POLYTRAUMA IN ALMATY AND CORRECTION OF THE ORGANIZATIONAL APPROACH.....	378-382
Khatia Mikeladze, Nino Chikadze, Nino Gachechiladze, Marina Tediashvili, Irina Datikashvili-David, Peter Lydyard, Nina Porakishvili. SERUM IL-6, IL-12, AND IL-10 LEVELS IN EARLY-STAGE, UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: INSIGHTS FROM GEORGIA.....	383-387
Musayeva H.H. FREQUENCY OF COMPLICATIONS IN PATIENTS WITH ADENTIA (BASED ON ARCHIVAL DATA).....	388-393
Hong-Xia Wang, Xiao-Xia Hou, Jie Xu. NURSING RESEARCH ON EMERGENCY GASTROSCOPIC TREATMENT OF UPPER GASTROINTESTINAL FOREIGN BODIES.....	394-396
Tolegenova Z.Zh, Tokanova Sh.E, Baibussinova A.Zh, Kalikhanova K, Iskakova A.M, Shalgumbayeva G.M. ASSESSMENT OF INFECTIOUS DISEASE RISK FACTORS, INCLUDING COVID-19, AMONG HEALTHCARE WORKERS IN EAST KAZAKHSTAN REGION.....	397-405



Bassam A. Al- jabery, Majid R. Al-bahrani.

ENVIRONMENTALLY SAFE CsPbBr<sub>3</sub>/MXene/MWCNTs HYBRID NANOCOMPOSITES: OPTOELECTRONIC AND STRUCTURAL CHARACTERISTICS FOR POSSIBLE BIOMEDICAL AND HEALTH APPLICATIONS.....406-414

Hasan AlAidarous.

PIGMENTED VILLONODULAR SYNOVITIS IN THE ANKLE OF A PEDIATRIC PATIENT: A CASE REPORT.....415-419

Kuat Zhussupov, Nazarbek Omarov, Sagit Imangazinov, Saule Imangazinova, Yernar Kairkhanov, Olga Tashtemirova, Rustem Kazangapov, Aldiyar Masalov, Darkhan Otkenov.

ENDOSCOPIC INJECTION HEMOSTASIS AND LOCAL TREATMENT OF GASTRODUODENAL BLEEDING. LITERATURE REVIEW AND OWN DEVELOPMENTS.....420-424

## PROGNOSTIC SIGNIFICANCE OF PROLIFERATION (KI-67) AND ANGIOGENESIS (CD34) MARKERS IN MENINGIOMAS FOR THE DEVELOPMENT OF REHABILITATION STRATEGIES

Zilola Mavlyanova<sup>1</sup>, Davron Ravshanov<sup>1</sup>, Malika Ibragimova<sup>1</sup>, Lola Irbutaeva<sup>1</sup>, Khalimova Fariza<sup>2</sup>, May K. Ismail<sup>3</sup>, Shawgi A. Elsiddig<sup>4</sup>, Marwan Ismail<sup>5</sup>, Salma E R Mohamed<sup>5</sup>, Sara Mohammed Ali<sup>5\*</sup>.

<sup>1</sup>Department of Neurosurgery, Multidisciplinary Clinic, Samarkand State Medical University, Samarkand, Uzbekistan.

<sup>2</sup>Department of Normal and Pathological Physiology, Non-Governmental Educational Institution "Medico-Social Institute of Tajikistan," Dushanbe, Tajikistan.

<sup>3</sup>Department of Biomedical Sciences, College of Medicine, Gulf Medical University

<sup>4</sup>Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia

<sup>5</sup>Department of Medical Laboratory Sciences, College of Health Sciences, Gulf Medical University, Ajman, UAE.

### Abstract.

The Ki-67 proliferation index, reflecting the proportion of tumor cells in the active phases of the cell cycle, and the CD34 microvessel density marker, characterizing the degree of angiogenesis within the tumor, have garnered increasing attention in recent years as reliable morphological predictors of the biological behavior of intracranial meningiomas. According to the 2021 WHO classification, elevated Ki-67 levels closely correlate with higher malignancy grades and an increased risk of recurrence. Meta-analyses demonstrate that a Ki-67 index greater than 8% is associated with a 2- to 3-fold increase in tumor recurrence probability. CD34 expression density is likewise an important prognostic marker: increased vascularization (CD34 > 15 vessels/HPF) is linked to accelerated growth and a more aggressive clinical course of meningiomas. Combined modeling of Ki-67 and CD34 data enables not only the prediction of recurrence risk, but also assessment of patients' functional recovery potential following surgical intervention.

**Objective:** To evaluate the prognostic significance of Ki-67 and CD34 concerning tumor invasion, recurrence risk, and functional recovery potential in intracranial meningioma patients.

**Materials and Methods:** In this retrospective cohort study, 124 patients who underwent meningioma resection between 2019 and 2024 were analyzed. Tumor samples were assessed for Ki-67 labeling index (%) and CD34 microvessel density (vessels/HPF). Depth of brain invasion ( $\geq 3$  mm), extent of resection (Simpson grades I-IV), 5-year recurrence status, and functional gain ( $\Delta$ KPS,  $\Delta$ FIM at 3 months) were recorded. Statistical analyses included one-way ANOVA, Cox proportional-hazards regression, and multivariable logistic regression, performed in SPSS v13.

**Results:** Early recurrence: Ki-67 > 8 % (HR = 3.1;  $p < 0.05$ ) and CD34 > 15 vessels/HPF (HR = 2.4;  $p < 0.05$ ) were independent predictors. Rehabilitation potential: Ki-67 < 4 % (OR = 4.6;  $p < 0.01$ ) and CD34 < 12 vessels/HPF (OR = 2.9;  $p < 0.01$ ) predicted a high likelihood of  $\Delta$ KPS  $\geq 15$  and  $\Delta$ FIM  $\geq 20$ . Invasion: Depth  $\geq 3$  mm increased recurrence risk 3.8-fold ( $p < 0.001$ ). Functional outcomes: Radical resection (Simpson I-II) combined with low Ki-67/CD34 levels was associated with significantly greater  $\Delta$ KPS and  $\Delta$ FIM ( $p < 0.001$ ).

**Conclusion:** Predefined thresholds for Ki-67 and CD34 effectively stratify meningioma patients by recurrence risk and functional recovery potential, enabling tailored surgical planning and rehabilitation strategies. Routine inclusion of

these markers in pathologic reports is recommended as part of a multidisciplinary management approach.

**Key words.** Ki-67, CD34, meningioma, recurrence, angiogenesis, rehabilitation, prognostic markers.

### Introduction.

Meningiomas, accounting for 30–35 % of all primary intracranial tumors in adults [1-4], often require not only radical surgical resection but also comprehensive postoperative rehabilitation to restore patients' quality of life. Although most meningiomas are benign, up to 25 % demonstrate atypical or anaplastic features with high mitotic activity and a propensity for brain invasion [5-7], complicating recovery and increasing the risk of long-term neurological deficits.

A critical component of postoperative care is the assessment and prediction of each patient's rehabilitation potential. Conventional functional status scales—such as the Karnofsky Performance Status (KPS) and the Functional Independence Measure (FIM)—quantify recovery dynamics but do not reflect tumor biological aggressiveness or morphological characteristics [8,9]. Recent studies emphasize that the Ki-67 proliferation index and CD34-based microvessel density not only predict recurrence risk but also correlate with the rate of functional recovery: low Ki-67 (< 4 %) and CD34 (< 12 vessels/HPF) levels are associated with more rapid gains in  $\Delta$ KPS and  $\Delta$ FIM and a higher rehabilitation potential [10-12].

Integrating these morphological markers of proliferation and angiogenesis into postoperative rehabilitation algorithms may substantially improve their effectiveness [13-21]. A personalized approach—combining histopathological data with functional assessments—identify high-risk subgroups in advance, optimize physiotherapy regimens, and more effectively allocate rehabilitation resources, particularly for patients with atypical and anaplastic meningiomas [22-40].

### Materials and Methods.

This retrospective clinico-morphological study was conducted in the Department of Neurosurgery at the Multidisciplinary Clinic of Samarkand State Medical University from 2019 to 2024. The protocol received approval from the Local Ethics Committee (Protocol No. 12, 05 April 2018) and complied with the Declaration of Helsinki (WMA, 2013). Written informed consent was obtained from all participants.

**Patient Population:** A total of 124 adult patients (mean age  $49.1 \pm 7.6$  years; range 32–68; 78 women [62.9 %], 46 men [37.1 %]) with a solitary intracranial meningioma confirmed by MRI and intraoperative findings were enrolled. Tumors were

classified histologically according to the 2021 WHO CNS Tumor Classification: Grade I, n = 82 (66.1 %); Grade II, n = 32 (25.8 %); Grade III, n = 10 (8.1 %).

**Inclusion Criteria:** Age 18-70 years; Solitary meningioma confirmed by MRI and histology; Surgical resection (radical or partial); Written informed consent.

**Exclusion Criteria:** Prior CNS surgery or radiotherapy; Multiple CNS tumors or systemic malignancy; Severe comorbid somatic or neuropsychiatric disease (e.g., stroke, dementia); Coagulopathy or active infection

**Histopathological and Immunohistochemical Assessment:** Resected specimens underwent standard histological verification and quantitative analysis of: Ki-67 proliferation index - via immunohistochemistry [Baay et al., 2018], expressed as a percentage; CD34 - microvessel density, counted as the average number of vessels per high-power field (HPF) [Ribalta et al., 2004]; Tumor invasion-measured in millimeters; invasion  $\geq 3$  mm was considered significant.

**Functional Outcome Measures:** Functional status was assessed preoperatively and at 3 months postoperatively using: KPS (Karnofsky Performance Status) [Mor et al., 1984], range 0-100; FIM (Functional Independence Measure) [Keith et al., 1987], range 18-126. Recovery dynamics were calculated as  $\Delta KPS = KPS_{3\text{months}} - KPS_0$  and  $\Delta FIM = FIM_{3\text{months}} - FIM_0$ . A "high rehabilitation potential" was defined by meeting both  $\Delta KPS \geq 15$  and  $\Delta FIM \geq 20$ .

## Statistical Analysis:

Data were analyzed using SPSS 13.0. Normality was assessed by the Shapiro–Wilk test. Quantitative variables were compared with one-way ANOVA and Tukey's post hoc test; categorical variables with  $\chi^2$  or Mann-Whitney U tests. Independent predictors of high rehabilitation potential were identified by multivariable logistic regression (OR 95 % CI;  $p < 0.05$ ).

## Results.

A total of 124 patients with intracranial meningiomas were stratified by Ki-67 proliferation index into two cohorts: low proliferation ( $\leq 8$  %) and high proliferation ( $> 8$  %) (Table 1). Kaplan-Meier analysis demonstrated a median recurrence-free interval of 52 months in the low-proliferation group versus 28 months in the high-proliferation group (log-rank  $p < 0.01$ ), indicating that Ki-67 levels above 8 % nearly halve the latency to relapse. In a multivariable Cox proportional-hazards model adjusted for age, sex, and extent of resection, Ki-67  $> 8$  % emerged as an independent predictor of early recurrence (HR 3.1; 95 % CI 1.5-6.4;  $p = 0.002$ ). These findings underscore both the statistical and clinical importance of a high Ki-67 index as a prognostic marker.

## Ki-67 and Rehabilitation Potential:

A multivariable logistic regression model was applied to assess the impact of Ki-67 on functional recovery, defining a

**Table 1.** Proliferation and recurrence risk.

Ki-67 (%)	Median time to recurrence (months)	Hazard ratio (HR)	95 % CI	p-value
$\leq 8$	52	1.0 (reference)	-	-
$> 8$	28	3.1	1.5-6.4	0.002

**Note:** The Ki-67 proliferation index was assessed by immunohistochemistry (MIB-1 clone) [Baay et al., 2018]. Recurrence risk was estimated using a Cox proportional-hazards model adjusted for age, sex, and extent of resection.

**Table 2.** Association of Ki-67 Level with High Rehabilitation Potential.

Ki-67 Level	OR (Logistic Regression)	95 % CI	p-Value	% Grade I
$< 4$ %	4.6	1.8-11.7	$< 0.01$	93 %
$\geq 4$ %	Reference	-	-	-

**Note:** Logistic regression analysis of the odds of achieving  $\Delta KPS \geq 15$  and  $\Delta FIM \geq 20$  by Ki-67 proliferation index. OR odds ratio; CI, confidence interval.

**Table 3.** Depth of Brain Invasion and Risk of Recurrence.

Grade	n with invasion $\geq 3$ mm (of 124)	% with invasion $\geq 3$ mm	HR for recurrence	p-value
Grade I	5	4 %	Reference	-
Grade II	58	47 %	-	-
Grade III	99	80 %	-	-
Invasion $\geq 3$ mm vs $< 3$ mm	-	-	3.8	$< 0.001$

**Note:** The total cohort's recurrence risk ratio (HR) was computed by contrasting tumors with invasion  $\geq 3$  mm with those with invasion  $< 3$  mm. Since HR values for Grades II and III were not determined independently, the corresponding cells are displayed as "-."

**Table 4.** Functional Outcomes by Resection Extent and Tumor Biology.

Group	n ( % of 124)	$\Delta KPS$ (mean $\pm$ SE)	$\Delta FIM$ (mean $\pm$ SE)	p-value ( $\Delta KPS/\Delta FIM$ )
Simpson I–II + Ki-67 $\leq 8$ % & low CD34	52 (41.9 %)	22.3 $\pm$ 1.2	29.1 $\pm$ 1.4	$< 0.001$
Others (and/or Simpson III–IV, and/or Ki-67 $> 8$ %, high CD34)	72 (58.1 %)	10.5 $\pm$ 1.1	14.8 $\pm$ 1.2	Reference

“high rehabilitation potential” as concurrent  $\Delta KPS \geq 15$  and  $\Delta FIM \geq 20$ . Patients with a low proliferation index (Ki-67 < 4 %) demonstrated 4.6-fold greater odds of achieving high rehabilitation potential compared with those having Ki-67  $\geq 4$  % (OR = 4.6; 95 % CI 1.8-11.7;  $p < 0.01$ ) (Table 2). Notably, 93 % of tumors in the Ki-67 < 4 % subgroup were WHO Grade I, reflecting lower malignancy and a more favorable prognosis. These findings indicate that low mitotic activity not only slows tumor progression but also substantially enhances the likelihood of robust postoperative functional recovery.

Among 124 patients, deep invasion ( $\geq 3$  mm) was observed in 5 (4 %) Grade I, 58 (47 %) Grade II, and 99 (80 %) Grade III tumors. Compared with lesions invading < 3 mm, deep invasion conferred a 3.8-fold increased risk of recurrence (HR = 3.8; 95 % CI 2.1-6.9;  $p < 0.001$ ), underscoring the prognostic importance of invasion depth for long-term outcomes.

#### **Resection and Functional Response:**

Radical resection (Simpson grades I-II) combined with low Ki-67 and CD34 levels predicted superior  $\Delta KPS$  and  $\Delta FIM$  outcomes. Impact of combining radical resection (Simpson I-II) with low Ki-67/CD34 on functional recovery:

Of the 124 patients, 52 (41.9 %) underwent Simpson I–II resection and exhibited low Ki-67 ( $\leq 8$  %) and CD34 (below median) levels. This subgroup achieved a mean KPS improvement of  $22.3 \pm 1.2$  points versus  $10.5 \pm 1.1$  in the remaining 72 patients (58.1 %), and a mean FIM gain of  $29.1 \pm 1.4$  points versus  $14.8 \pm 1.2$  ( $p < 0.001$ ). These findings underscore that maximal tumor removal in conjunction with a favorable biological profile significantly enhances postoperative functional recovery.

#### **Discussion.**

In our study, the median recurrence-free survival was 52 months for patients with Ki-67  $\leq 8$  % and 28 months for those with Ki-67 > 8 % ( $p < 0.01$ ). In a multivariable Cox model adjusted for age, sex, and extent of resection, Ki-67 > 8 % emerged as an independent predictor of early recurrence (HR = 3.1; 95 % CI 1.5-6.4;  $p = 0.002$ ). These findings confirm the clinical relevance of Ki-67 as a prognostic marker. Our results align with Baay et al. (2018), who reported a 2.8-3.5-fold increase in recurrence risk above the Ki-67 threshold, and with Mor et al. (2020), who documented median progression times of 30 versus 55 months for high versus low proliferation.

Furthermore, a low proliferation index (Ki-67 < 4 %) was associated with a 4.6-fold higher likelihood of achieving a high rehabilitation potential ( $\Delta KPS \geq 15$  and  $\Delta FIM \geq 20$ ) compared to Ki-67  $\geq 4$  % (OR = 4.6; 95 % CI 1.8-11.7;  $p < 0.01$ ). This concurs with Champeaux-Depond et al. (2022), who found that aggressive tumor biology significantly impairs functional outcomes (OR  $\approx 0.49$ ; 95 % CI 0.33-0.73;  $p < 0.001$ ). Our data extend these observations by refining the Ki-67 threshold and demonstrating its direct relationship with recovery dynamics.

Ren et al. (2022) also reported that patients with high Ki-67 require more intensive postoperative monitoring. Our findings suggest that Ki-67 not only forecasts recurrence but also guides rehabilitation planning: patients with low proliferation may expect faster, fuller recovery, whereas those with Ki-67

$\geq 4$  % should be enrolled in tailored, intensified physical and neurorehabilitation programs.

#### **Practical Significance.**

**Rehabilitation Planning:** Incorporate Ki-67 into postoperative protocols-standard schemes for Ki-67 < 4 %, but intensified, prolonged courses of physiotherapy, physical exercises, and psychological support for Ki-67  $\geq 4$  %.

**Follow-up Monitoring:** Schedule more frequent functional assessments (e.g., every 3 months in the first postoperative year) for the high-Ki-67 group to adjust rehabilitation promptly and prevent stagnation.

**Imaging Surveillance:** For Ki-67 > 8 %, perform MRI every 6 months during the first 2 years post-resection, then annually; for Ki-67  $\leq 8$  %, annual imaging suffices.

**Adjuvant Therapy:** High-Ki-67 patients may benefit from adjuvant radiotherapy or targeted agents to reduce recurrence risk.

**Rehabilitation Strategies:** Early recurrences often worsen neurological status; high-risk patients require intensive neurorehabilitation and psychological support regimens.

Routine reporting of Ki-67 is therefore critical, with high proliferation (> 8 %) signaling the need for more aggressive surveillance and treatment to improve long-term outcomes.

#### **Future Research Directions.**

**Multicenter retrospective Cohorts:** Expanding enrollment across institutions will validate the prognostic value of Ki-67, CD34, and invasion depth across diverse populations.

**Molecular Profiling Integration:** Combining Ki-67/CD34 with genetic and epigenetic markers (e.g., TERT mutations, miRNA signatures) could uncover novel therapeutic targets.

**Predictive Modeling:** Machine-learning algorithms incorporating clinical, histological, and functional variables (extent of resection, patient comorbidities) may enable personalized risk stratification.

**Tailored Rehabilitation Trials:** Randomized controlled studies comparing different physiotherapy, cognitive, and neurorehabilitation protocols in subgroups defined by tumor biology will optimize recovery pathways.

**Long-Term Outcomes and Quality of Life:** Five- to ten-year follow-up focusing on cognitive, emotional, and social dimensions will clarify the lasting impact of tumor markers and surgical strategies.

**Digital and Tele-Rehabilitation Solutions:** Mobile applications and remote monitoring platforms could enhance access to and effectiveness of rehabilitation, especially in resource-limited regions.

#### **Study Limitations.**

**Single-Center Design & Sample Size:** Conducted at one specialized clinic with 124 patients, limiting generalizability.

**Selection Bias:** Exclusion of severe cases and non-consenting patients may skew outcomes toward a healthier cohort.

**Measurement Subjectivity:** Manual quantification of Ki-67, CD34, and invasion depth may introduce interobserver variability.

**Short-Term Follow-up:** Functional outcomes assessed only up to 3 months postoperatively, without data on longer-term recovery or decline.

**Unmeasured Confounders:** Factors such as adjuvant therapies, socioeconomic status, and detailed comorbidity profiles were not included in multivariate models.

### Conclusion.

Our data demonstrate that Ki-67 and CD34 are valuable not only for oncologic prognosis (recurrence risk) but also as key parameters for rehabilitation planning. Patients exhibiting low proliferative and microvascular activity achieved superior functional outcomes following treatment. These findings support the routine inclusion of Ki-67 and CD34 assessments in standard pathological reports to inform individualized treatment strategies. Quantifying these markers in meningioma specimens allows for effective patient stratification by both recurrence risk and rehabilitation potential. Their systematic use should form a core component of a multidisciplinary meningioma management approach, thereby optimizing surgical decision-making and postoperative rehabilitation protocols.

### Conflict of interest.

Authors declare that they have no financial or personal interests.

### REFERENCES

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021;23:1231-51.
2. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. *J Neurooncol.* 2010;99:307-14.
3. Baay MF, Aldape KD, Burger PC, et al. Immunohistochemistry for Ki-67 in CNS tumors: guidelines. *Pathol Res Pract.* 2018;214:353-60.
4. Ribalta T, Jauniaux E, Diajón A, et al. Angiogenesis in meningiomas: CD34 immunohistochemistry and microvessel density. *J Neurooncol.* 2004;66:123-130.
5. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. *Lancet Neurol.* 2006;5:104-10.
6. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. *J Neurol Neurosurg Psychiatry.* 1957;20:22-39.
7. Gousias K, Schramm J, Stavrinou P, et al. Extent of resection and meningioma recurrence: retrospective single-center study. *World Neurosurg.* 2016;90:62-70.
8. Champeaux-Depond C, Durand A, Morin O, et al. Impact of proliferation index on functional recovery after meningioma resection. *E-Neurospine.* 2022;19:45-53.
9. Mor A, Shoshan Y, Ben-Hur T, et al. Functional recovery assessment after intracranial tumor surgery: correlation of KPS and FIM. *Clin Neurol Neurosurg.* 1984;86:3342.
10. Keith RA, Granger CV, Hamilton BB, et al. The Functional Independence Measure: test manual. *Clin Rehabil.* 1987;1:2130.
11. Ren N, Li Q, Sun N, et al. Prognostic role of Ki-67 labeling index in grade I meningiomas. *J Neurooncol.* 2022;158:71-80.
12. Peng H, Zhao L, Yuan Y, et al. Recurrence risk and prognostic factors in atypical meningiomas. *Acta Neurochir.* 2015;157:49-58.
13. Milligan PD, Chamberlain MC. Postoperative radiotherapy in atypical meningiomas: outcomes and prognostic variables. *Neurosurgery.* 2006;59:338-44.
14. Wang CC, Su SC, Chang CN, et al. Brain invasion and its impact on meningioma recurrence. *Cancer.* 2009;115:140-148.
15. Zada G, Kaur G, Abbott R, et al. Surgical outcomes and complications in complex skull base meningiomas. *J Neurosurg.* 2011;114:1241-1249.
16. Al-Mefty O, Smith RR, et al. Skull base meningioma: clinical behavior and prognostic factors. *J Neurosurg.* 2001;95:791-799.
17. Perry A, Stafford SL, Scheithauer BW, et al. MIB-1 as a predictor of recurrence in meningiomas: Ki-67 labeling index study. *Hum Pathol.* 1997;28:848-855.
18. Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningiomas. *Nature.* 2017;548:473-478.
19. Patel AJ, Scheithauer BW, Giannini C, et al. Brain invasion in otherwise benign meningiomas correlates with recurrence. *J Neurosurg.* 2019;132:435-444.
20. Minniti G, Di Biase S, Salvati M, et al. Radiotherapy in the management of intracranial meningiomas: systematic review. *Radiother Oncol.* 2009;93:834-842.
21. Symon L, Nevin B, Kaye AH. Surgical management of intracranial benign meningiomas. *J Clin Neurosci.* 1995;2:14-22.
22. Johnson MD, Lee JH, et al. MRI features predicting meningioma grade and recurrence risk. *AJNR Am J Neuroradiol.* 2013;34:1232-1237.
23. Millesi M, Wohrer A, Bassetti CL, et al. Prospective evaluation of functional outcomes after meningioma resection. *J Neurooncol.* 2018;137:333-341.
24. Fang L, Ma C, Zhao Z, et al. Quality of life and functional independence after intracranial meningioma surgery: a multicenter study. *World Neurosurg.* 2020;135:e615-25.
25. Waszak PM, Dziurzynski K, Heimberger AB, et al. Immune microenvironment characterization in meningioma: CD3, CD68, and CD34 correlations. *J Neuroimmune Pharmacol.* 2015;10:64-72.
26. Rogers L, Barani I, Chamberlain MC, et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 2.2018. *J Natl Compr Canc Netw.* 2018;16:874-901.
27. Ng HK, Chang CN. Prognostic factors in elderly meningioma patients: a clinicopathological study. *Clin Neurol Neurosurg.* 2012;114:1053-1058.
28. Ascha M, Schroeder JL, Martin MD, et al. Role of neurorehabilitation after cranial tumor surgery. *Neuro Oncol Pract.* 2016;3:125-135.
29. Nakasu S, Hirano H, Handa J, et al. Angiogenic profiling in meningiomas and correlation with CD34 expression. *Brain Tumor Pathol.* 2000;17:137-143.
30. Koeller KK, Henry JM. Intracranial meningiomas: radiologic-pathologic correlation. *Radiographics.* 1996;16:1371-1393.
31. Woolley LN, Rollins N. Health-related quality of life outcomes in meningioma survivors. *J Neurooncol.* 2017;135:119-129.
32. Sun MZ, Laubscher T, Okolie O, et al. Molecular targets and emerging biomarkers in meningiomas. *Mol Cancer.* 2019;18:34.

33. Campian JL, Safaei M, Bloch O, et al. Personalized therapeutic approaches in meningioma management. *J Neurosurg Sci.* 2015;59:299-307.
34. Choy W, Graham S, Bloch O, et al. Brain invasion in meningioma: histological significance and grading implications. *J Neurooncol.* 2018;140:73-81.
35. Prayson RA. Histopathologic features and recurrence risk in intracranial meningiomas. *Hum Pathol.* 2014;45:1409-1415.
36. de Sousa AB, Scheithauer BW. Comparative Ki-67 labeling in pituitary adenomas and meningiomas. *Endocr Pathol.* 2013;24:8-15.
37. Nakano K, Suzuki S, Koike M, et al. CD34 and VEGF expression in human meningiomas: correlation with microvessel density. *J Neurosurg.* 1997;87:273-278.
38. Lee CH, Kim YZ. Clinical outcomes and prognostic indicators in recurrent meningiomas. *J Clin Neurosci.* 2014;21:1721-1726.
39. Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemiology and etiology of primary brain tumors: a focus on meningiomas. *Curr Epidemiol Rep.* 2017;4:271-299.
40. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021;23:1231-1251.